3-hydroxy-3-(4-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one | 728012-28-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-hydroxy-3-(4-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one
• 英文别名: 3-hydroxy-3-(4-methoxyphenyl)-5-methyl-1H-indol-2-one
• CAS: 728012-28-0
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.3
• InChiKey: FFSCCFSRJCDSER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-hydroxy-3-(4-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one 在 2,2'-联吡啶 、 manganese(III) triacetate dihydrate 、 溶剂黄146 、 tin(ll) chloride 、 iron(II) chloride 作用下， 以 癸烷 、 乙腈 为溶剂， 反应 24.0h， 生成 2-(4-methoxyphenyl)-6-methyl-4H-benzo[d][1,3]oxazin-4-one
  参考文献：
  名称：

  FeCl2 催化芳基过氧吲哚重排为 1,3-苯并恶嗪-4-一

  摘要：

  我们报告了 FeCl 2催化的芳基过氧吲哚自由基重排为 1,3-苯并恶嗪-2-酮，以中等至良好的收率获得各种芳基取代的 1,3-苯并恶嗪-4-酮。从机制上讲，过氧吲哚的这种骨架重排通过自由基途径进行，并得到一系列实验结果和 DFT 研究的充分支持。

  DOI：

  10.1002/adsc.202201308
• 作为产物：
  描述：

  3-(4-Methoxyphenyl)-5-methyl-1,3-dihydroindol-2-one 在 air 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以79%的产率得到3-hydroxy-3-(4-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  N-Heterocyclic Carbene-Palladium(II)-1-Methylimidazole Complex Catalyzed α-Arylation of Oxindoles with Aryl Chlorides and Aerobic Oxidation of the Products in a One-Pot Procedure

  摘要：

  NHC-Pd(II)-Im complex 1 was found to be an effective catalyst for the alpha-arylation of unprotected oxindoles with aryl chlorides to give products 4 in 44-98% yields under a N-2 atmosphere. Furthermore, if the reactions were first performed under conditions identical to those for the alpha-arylation reaction for 12 hand then exposed to air for another 3 h, 3-aryl-3-hydroxy-2-oxindoles 5 can be obtained in 49-84% yields In a one-pot procedure.

  DOI：

  10.1021/ol400186b

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US08030499B2

  公开（公告）日：2011-10-04

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  本发明旨在提供一种对精氨酸加压素V1b受体相关的病理状况有效的药物。更具体地说，本发明旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫性疾病、脱发等具有治疗或预防作用的药物。经过密集研究，发现了一种新型的1,3-二氢吲哚-2-酮化合物和一种与杂环芳香环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性、良好的脑穿透性和高血浆浓度，从而实现了上述目标。
• US8030499B2
  申请人：——

  公开号：US8030499B2

  公开（公告）日：2011-10-04
• <i>N</i>-Heterocyclic Carbene-Palladium(II)-1-Methylimidazole Complex Catalyzed α-Arylation of Oxindoles with Aryl Chlorides and Aerobic Oxidation of the Products in a One-Pot Procedure
  作者：Zheng-Kang Xiao、Hui-Ying Yin、Li-Xiong Shao

  DOI：10.1021/ol400186b

  日期：2013.3.15

  NHC-Pd(II)-Im complex 1 was found to be an effective catalyst for the alpha-arylation of unprotected oxindoles with aryl chlorides to give products 4 in 44-98% yields under a N-2 atmosphere. Furthermore, if the reactions were first performed under conditions identical to those for the alpha-arylation reaction for 12 hand then exposed to air for another 3 h, 3-aryl-3-hydroxy-2-oxindoles 5 can be obtained in 49-84% yields In a one-pot procedure.
• FeCl ₂ ‐Catalyzed Rearrangement of Aryl Peroxyoxindole into 1,3‐Benzooxazin‐4‐One
  作者：Nirmala Mohanta、Pragnya Paramita Samal、Sailaja Krishnamurty、Boopathy Gnanaprakasam

  DOI：10.1002/adsc.202201308

  日期：2023.2.21

  We report an FeCl2-catalyzed radical rearrangement of aryl peroxyoxindoles into 1,3-benzooxazin-2-ones to obtain a variety of aryl substituted 1,3-benzooxazin-4-ones in moderate to good yields. Mechanistically, this skeletal rearrangement of peroxyoxindoles proceeded via radical pathway and was well supported with a series of experimental findings and DFT studies.

  我们报告了 FeCl 2催化的芳基过氧吲哚自由基重排为 1,3-苯并恶嗪-2-酮，以中等至良好的收率获得各种芳基取代的 1,3-苯并恶嗪-4-酮。从机制上讲，过氧吲哚的这种骨架重排通过自由基途径进行，并得到一系列实验结果和 DFT 研究的充分支持。